human retinal progenitor cells / ReNeuron - LARVOL DELTA

Safety and Tolerability of hRPC in Retinitis Pigmentosa (clinicaltrials.gov) - P1/2; N=29; Active, not recruiting; Sponsor: ReNeuron Limited; Recruiting ➔ Active, not recruiting; Trial completion date: Mar 2023 ➔ Dec 2023; Trial primary completion date: Sep 2021 ➔ Jun 2022

Clinical • Enrollment closed • Trial completion date • Trial primary completion date • Genetic Disorders • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Prostate Cancer • Retinal Disorders • Retinitis Pigmentosa • Transplantation

Safety and Tolerability of hRPC in Retinitis Pigmentosa (clinicaltrials.gov) - P1/2; N=33; Recruiting; Sponsor: ReNeuron Limited; Active, not recruiting ➔ Recruiting

Clinical • Enrollment open • Genetic Disorders • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Prostate Cancer • Retinal Disorders • Retinitis Pigmentosa • Transplantation

Safety and Tolerability of hRPC in Retinitis Pigmentosa (clinicaltrials.gov) - P1/2; N=33; Active, not recruiting; Sponsor: ReNeuron Limited; Recruiting ➔ Active, not recruiting

Enrollment closed • Genetic Disorders • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Prostate Cancer • Retinal Disorders • Retinitis Pigmentosa • Transplantation

Safety and Tolerability of hRPC in Retinitis Pigmentosa (clinicaltrials.gov) - P1/2; N=33; Recruiting; Sponsor: ReNeuron Limited; N=21 ➔ 33; Trial completion date: Jul 2021 ➔ Mar 2023; Trial primary completion date: Jan 2020 ➔ Sep 2021

Clinical • Enrollment change • Trial completion date • Trial primary completion date • Genetic Disorders • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Prostate Cancer • Retinal Disorders • Retinitis Pigmentosa • Transplantation